EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

EQT Sweden United Kingdom Germany

Proceeds will fund clinical development of oncology and immunology therapeutics derived from innovative antibody payload platform         Mark Throsby, industry veteran and former CSO of Merus, joins as Executive ChairView original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-54-million-series-a-financing-of-atb-therapeutics-302308732.html